ReviewRegenerative biomaterials2026
Recent advances in biomaterials for osteosarcoma treatment.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A 'three-axis synergy' immunotherapeutic strategy for malignant bone tumors based on natural bioactives and bioactive materials.Bioactive materials · 2026Review
- Mimicking the Osteosarcoma Bone Microenvironment Using MEW-Printed PCL Scaffolds.Macromolecular bioscience · 2026Article
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a highly aggressive bone malignancy with poor prognosis due to high metastasis and drug resistance. Conventional treatments often result in systemic toxicity and limited efficacy, highlighting the need for more precise and integrative approaches. Biomaterials with excellent biocompatibility and functional tunability have emerged as promising tools to enhance local therapy and support bone regeneration. This review summarizes recent advances in the application of natural, synthetic and composite biomaterials in four key areas: drug delivery, gene therapy, immunotherapy and post-resection bone repair. To provide a systematic perspective, we compiled and classified 64 representative studies published between 2021 and 2025, comparing biomaterial-based delivery strategies ranging from single-material carriers to multifunctional composite platforms. Particular focus is given to stimuli-responsive systems and scaffolds that integrate antitumor activity with regenerative capacity. By outlining emerging strategies and material platforms, this review offers a concise reference for the rational design of biomaterials addressing the dual challenge of tumor eradication and skeletal reconstruction. Interdisciplinary collaboration will be key to advancing these systems toward clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.